The Challenges in Manufacturing Biologics
Biologic therapies are typically derived from living organisms. They are made by genetically engineering living cells, and a high level of precision is required in the commercial manufacturing process to produce a consistent biologic product each time. The protein produced by the cells will be influenced by individual cell characteristics, and the environment and nutrients provided during the manufacturing process.

▶︎
The Evolution of Biotechnology – The Arrival of Biosimilars

▶︎
How Biosimilars Are Made: Inside Biologic Drug Manufacturing

▶︎
Anatomy of a Fracture as a Result of Systemic Bone Loss

▶︎
Biologics Manufacturing: Video 5 -- Fill, Finish and Packaging

▶︎
The Hunt for New Checkpoint Inhibitors - Amgen Science

▶︎
AI in Drug Discovery: How Scientists are Leveraging Technology in Biotech Research

▶︎
IgG4-RD Explained: From Delayed Diagnosis to Improving Care

▶︎
Postmenopausal Osteoporosis

▶︎
The Next Generation of Biomanufacturing at Amgen

▶︎
Biotechnology by Amgen: Using Innovation to Advance Medicine

▶︎
Advancing Obesity Research

▶︎
Regulation of Osteoclast Activity

▶︎
BiTE® Immunotherapy: The Next Generation of Cancer Treatment

▶︎
Biologics Manufacturing : Video 1 - Clean Environment

▶︎
What Are Biosimilars? How Amgen Is Providing More Treatment Options

▶︎
Introduction to Bone Biology

▶︎
Inside Amgen’s Next-Generation Labs | Faster, Smarter Small Molecule Drug Discovery

▶︎
Protein Engineering: Unlocking the Power of Proteins | Amgen Science

▶︎
